Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Zenith believes Aussie market neutral funds offer out-performance and diversification across the board

Monday, February 11, 2013

Beverly Chandler, Opalesque London: Australian investment researchers, Zenith Investment Partners have published their 2013 Equity Market Neutral Review. The firm examined seven of what they consider the best of the market neutral funds offered to Australian investors.

Zenith believes that one of the key strengths of the sector is the range of different strategies market neutral funds can employ, with the funds they cover investing as quantitative managers, fundamental stock pickers and a relative value strategy. Daniel Liptak, Head of Alternatives at Zenith Investment Partners explains: "This results in a list of funds which have limited correlation to the broader equity market, but also importantly, limited correlation to each other."

Liptak quotes George Soros "It is not whether you’re right or wrong that’s important, but how much money you make when you are right and how much money you lose when you’re wrong" in his review of the sector. Liptak believes that Australian market neutral funds provide capital preservation and more reasonable participation in alpha than the average long only Australian equity fund but also, he writes, they are among the best performing strategies globally.

As a group, the Zenith Investment Grade Market Neutral Funds 2013, returned a cumulative return of 246.94% in the 10 years to October 2012 (net of fees). Over the same time the broad Australian market has returned 128.17%......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its